日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Evaluating the Compatibility of New Recombinant Protein Antigens (Trivalent NRRV) with a Mock Pentavalent Combination Vaccine Containing Whole-Cell Pertussis: Analytical and Formulation Challenges

评估新型重组蛋白抗原(三价 NRRV)与含有全细胞百日咳的模拟五价联合疫苗的兼容性:分析和配方挑战

Prashant Kumar, David A Holland, Kathryn Secrist, Poorva Taskar, Brandy Dotson, Soraia Saleh-Birdjandi, Yetunde Adewunmi, Jennifer Doering, Nicholas J Mantis, David B Volkin, Sangeeta B Joshi

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

一种基于铁蛋白的COVID-19纳米颗粒疫苗,可在非人灵长类动物中诱导产生强效、持久、广谱的中和抗血清。

Payton A-B Weidenbacher # ,Mrinmoy Sanyal # ,Natalia Friedland # ,Shaogeng Tang ,Prabhu S Arunachalam ,Mengyun Hu ,Ozan S Kumru ,Mary Kate Morris ,Jane Fontenot ,Lisa Shirreff ,Jonathan Do ,Ya-Chen Cheng ,Gayathri Vasudevan ,Mark B Feinberg ,Francois J Villinger ,Carl Hanson ,Sangeeta B Joshi ,David B Volkin ,Bali Pulendran ,Peter S Kim

Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate

关联物理化学和生物学特性来定义 rAAV 候选疫苗的关键质量属性

Prashant Kumar, Michael Wang, Ozan S Kumru, John M Hickey, Julio Sanmiguel, Nerea Zabaleta, Luk H Vandenberghe, Sangeeta B Joshi, David B Volkin

Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants

用铝盐和 CpG 佐剂配制的 SARS-CoV-2 受体结合域 (RBD) 抗原的抗原佐剂相互作用、稳定性和免疫原性特征

Sakshi Bajoria, Kawaljit Kaur, Ozan S Kumru, Greta Van Slyke, Jennifer Doering, Hayley Novak, Sergio A Rodriguez Aponte, Neil C Dalvie, Christopher A Naranjo, Ryan S Johnston, Judith Maxwell Silverman, Harry Kleanthous, J Christopher Love, Nicholas J Mantis, Sangeeta B Joshi, David B Volkin

Molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine candidate for rotavirus

分子工程提高抗原质量并实现轮状病毒三价亚单位候选疫苗的一体化生产

Neil C Dalvie #, Joseph R Brady #, Laura E Crowell, Mary Kate Tracey, Andrew M Biedermann, Kawaljit Kaur, John M Hickey, D Lee Kristensen 2nd, Alexandra D Bonnyman, Sergio A Rodriguez-Aponte, Charles A Whittaker, Marina Bok, Celina Vega, Tarit K Mukhopadhyay, Sangeeta B Joshi, David B Volkin, Vivian

The Science is There: Key Considerations for Stabilizing Viral Vector-Based Covid-19 Vaccines

科学依据:稳定基于病毒载体的 Covid-19 疫苗的关键考虑因素

Daan J A Crommelin, David B Volkin, Karin H Hoogendoorn, Anthony S Lubiniecki, Wim Jiskoot

Mechanism of Thimerosal-Induced Structural Destabilization of a Recombinant Rotavirus P[4] Protein Antigen Formulated as a Multi-Dose Vaccine

硫柳汞诱导重组轮状病毒 P[4] 蛋白抗原(多剂量疫苗)结构不稳定的机制

Kawaljit Kaur, Jian Xiong, Nishant Sawant, Sanjeev Agarwal, John M Hickey, David A Holland, Tarit K Mukhopadhyay, Joseph R Brady, Neil C Dalvie, Mary Kate Tracey, Kerry R Love, J Christopher Love, David D Weis, Sangeeta B Joshi, David B Volkin

Short-term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus

在受到痘苗病毒攻击的小鼠中,用氢氧化铝和 CpG 佐剂接种天花 A33、B5、L1 或 A27 蛋白亚单位疫苗产生的短期和长期保护性免疫反应

Yuhong Xiao, Yuhong Zeng, Carole Schante, Sangeeta B Joshi, George W Buchman, David B Volkin, C Russell Middaugh, Stuart N Isaacs

A C-terminal Pfs48/45 malaria transmission-blocking vaccine candidate produced in the baculovirus expression system

在杆状病毒表达系统中产生的 C 端 Pfs48/45 疟疾传播阻断候选疫苗

Shwu-Maan Lee, John M Hickey, Kazutoyo Miura, Sangeeta B Joshi, David B Volkin, C Richter King, Jordan L Plieskatt

Preformulation Characterization and Stability Assessments of Secretory IgA Monoclonal Antibodies as Potential Candidates for Passive Immunization by Oral Administration

分泌型 IgA 单克隆抗体作为口服被动免疫潜在候选物的预制剂表征和稳定性评估

Yue Hu, Ozan S Kumru, Jian Xiong, Lorena R Antunez, John Hickey, Yang Wang, Lisa Cavacini, Mark Klempner, Sangeeta B Joshi, David B Volkin